Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 185 results found. Search for [ COVAXIN trial ]

Results 20 to 40 of 185
BusinessToday.In
January 5, 2021
It's great to see India's leadership in scientific innovation and vaccine manufacturing capability as the world works to end the COVID-19 pandemic, tweets the billionaire philanthropist


Joe C Mathew
January 4, 2021
Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine, Bharat Biotech did not try to supress the side effects of vaccine by giving paracetamol to the volunteers


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Defending Covaxin, the Bhart Biotech Chairman said that his company has tremendous experience in developing vaccines; more than 70 articles on data related to Covaxin have been published in various journals


BusinessToday.In
January 4, 2021
Both the vaccines got approval for emergency use authorisation on Sunday. They're both administered in two doses, the DCGI said in the permission letter


BusinessToday.In
January 4, 2021
Coronavirus vaccine: China has not done any efficacy trials, Russia also has not done any efficacy trials. We are doing efficacy trials on 26,000 people in the third phase, he said


BusinessToday.In
January 4, 2021
Cadila Healthcare share touched an intraday high of Rs 492.95, rising 3.02% against previous close of Rs 478.50 on BSE


BusinessToday.In
January 4, 2021
The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults


BusinessToday.In
January 3, 2021
Calling it a great day for the country, AIIMS Director Dr Randeep Guleria said that initially Serum-AstraZeneca's Covishield will be administered to the people


Reuters
January 3, 2021
India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine


BusinessToday.In
January 3, 2021
COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines


BusinessToday.In
January 3, 2021
Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November


Reuters
January 2, 2021
Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


Reuters
December 30, 2020
The result is based on interim analysis of data from its Phase III clinical trial


BusinessToday.In
December 29, 2020
The chief executive of Serum Institute - the biggest vaccine maker in the world by volume - said all trial data for Covishield has been provided to authorities in the UK and India as \"nobody wants to risk safety\"


PTI
December 28, 2020
Official sources said around 300 people who returned from the UK, where a new strain of coronavirus has emerged recently, were yet to be traced


Reuters
December 27, 2020
Coronavirus vaccine: Russia launched a voluntary vaccination programme with the Russia-made Sputnik V vaccine earlier in December, starting with the most vulnerable groups in Moscow


PTI
December 27, 2020
Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine


BusinessToday.In
December 26, 2020
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency


PAGES 2 OF 10  12345